Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock, no par value
-
Total 13F shares
-
23,663,852
-
Share change
-
-1,077,087
-
Total reported value
-
$40,697,713
-
Put/Call ratio
-
15%
-
Price per share
-
$1.72
-
Number of holders
-
46
-
Value change
-
-$4,573,104
-
Number of buys
-
18
-
Number of sells
-
28
Institutional Holders of Cyclerion Therapeutics, Inc. - Common Stock, no par value (CYCN) as of Q4 2021
As of 31 Dec 2021,
Cyclerion Therapeutics, Inc. - Common Stock, no par value (CYCN) was held by
46 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
23,663,852 shares.
The largest 10 holders included
Slate Path Capital LP, MFN Partners Management, LP, Artal Group S.A., FMR LLC, VANGUARD GROUP INC, PURA VIDA INVESTMENTS, LLC, GEODE CAPITAL MANAGEMENT, LLC, TWO SIGMA ADVISERS, LP, Ikarian Capital, LLC, and BlackRock Inc..
This page lists
46
institutional shareholders reporting positions in this security
for the Q4 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.